Therapure Biopharma Launches Biologics Division as Evolve Biologics™, an Innovative Plasma-Derived Therapeutics Company
March 23 2018 - 7:03PM
Business Wire
New plasma products and technology company led
by experienced senior management team, with industry veteran Blaine
Forshage as Chief Executive Officer
Dedicated to commercializing proprietary
PlasmaCap EBA® technology to efficiently meet growing global demand
for plasma-derived therapeutics
Pipeline of product candidates, initially
focused on commercialization of intravenous immunoglobulin (“IVIG”)
and human serum albumin (“Albumin”) in the U.S. and Canadian
markets
Therapure Biopharma Inc. (“Therapure”) today announced it has
launched its plasma products and technology division as Evolve
Biologics (“Evolve”), an innovative developer of plasma-derived
therapeutics, led by an experienced senior management team.
Evolve’s leadership team consists of Chief Executive Officer
Blaine Forshage; Chief Commercial Officer, David Holliday; and
Chief Financial Officer, Gregory Gould. All three industry veterans
bring significant experience in the global plasma-derived
therapeutics market.
“Today we publicly launch our strategy to realize the value in
Therapure’s proven technology and team, through a company dedicated
to the development of plasma-derived therapeutics for patients with
rare chronic diseases and acute conditions,” said Gabriel de Alba,
Chairman of Therapure and Managing Director and Partner at Catalyst
Capital Group Inc. “Over the past seven years, we’ve carefully
built the vision and capabilities for an innovative plasma-derived
therapeutics business. Now, with an experienced, committed team led
by Mr. Forshage, we’re ready to begin executing on our vision.”
Mr. Forshage added, “With the new protein discoveries,
indications and diagnoses driving global demand for plasma-derived
therapeutics, it’s time for our industry to innovate beyond the
plasma fractionation technologies originally developed in the
1940s. Our proprietary PlasmaCap EBA® technology is aimed at
producing improved yields of many plasma-based proteins with
greater efficiencies from the same liter of plasma. It is our goal
to use this technology to commercialize an exciting portfolio of
plasma-derived therapeutics, and we currently have two major
proteins – IVIG and Albumin advancing in development.”
As Chief Executive Officer, Mr. Forshage brings 25 years of
experience in the healthcare and biologics market, with over 17
years at Baxter/Baxalta, most recently as North American Region
Head (General Manager) for Baxalta Inc. Following his early career
in sales, he served in multiple positions of increasing
responsibility for Baxter/Baxalta and launched several brands in
the plasma and hemophilia marketplace. Mr. Forshage earned a BS in
Public Health and was recognized as a Distinguished Military
Graduate from Texas A&M University. Upon graduation, Mr.
Forshage served for two years with the United States Army Medical
Corps.
David Holliday recently joined Evolve as Chief Commercial
Officer, bringing over 30 years of pharmaceutical and biologics
experience. He has successfully launched and commercialized several
significant brands, including ones in the UK, US and global
markets, most recently as VP Commercial Operations for Octapharma
US. Prior to that he was the Global Vice President of Marketing
Operations & Hemophilia for Baxter BioScience, as well as
running their UK Bioscience Business, following a 17-year career
with Novartis. Mr. Holliday has a DMS from Kingston University in
London, UK.
Gregory Gould, Evolve’s Chief Financial Officer, has over 20
years of business experience in the biotech and life sciences
market, including 17 years as a public company CFO at several
NASDAQ- and NYSE-listed companies. He has closed on several
transactions including in-licensing and out-licensing of products,
buying and selling of products and divisions, and the sale of three
publicly traded companies to maximize shareholder value. Mr. Gould
started his career at Arthur Andersen LLP, has a BS in business
administration from the University of Colorado and is a Certified
Professional Accountant.
PlasmaCap EBA® is an innovative technology for efficient capture
of plasma proteins at higher yields and purities from human blood
plasma. The technology uses expanded bed adsorption (EBA)
chromatography to capture plasma proteins directly from plasma or
fractionated plasma materials without the use of inefficient and
potentially damaging cold ethanol. PlasmaCap EBA® has been able to
demonstrate more efficient yields of plasma-based proteins of
therapeutic value.
About Evolve Biologics™
Evolve Biologics innovates and aims to commercialize
plasma-derived therapeutics, using its proprietary PlasmaCap EBA®
purification technology to more efficiently and effectively meet
growing global patient demand for these products. Evolve is
currently in the process of developing a portfolio of product
candidates, including IVIG, which is currently in a Phase III
clinical trial, and Albumin. The organization is headquartered in
Mississauga, Ontario (Canada). For more information, please visit
www.evolvebiologics.com.
This press release contains forward-looking statements within
the meaning of Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities Exchange Act of 1934, as
amended. All opinions, forecasts, projections, future plans or
other statements, other than statements of historical fact, are
forward-looking statements. Forward-looking statements involve
risks and uncertainties, including uncertainties regarding the
matters described in this press release and the impact it may have
on Therapure Biopharma Inc. Forward-looking statements speak only
as of the date of this press release, and Therapure Biopharma Inc.
does not assume any obligation to publicly update or revise any
forward-looking statements, whether as a result of new information
or for any other reason, except as required by law.
Evolve Biologics™ is a trademark of Therapure Biopharma Inc.
Copyright ©2018
View source
version on businesswire.com: https://www.businesswire.com/news/home/20180323005772/en/
Gagnier CommunicationsJeffrey Mathews / Dan Gagnier / Patrick
Reynolds+1-646-569-5711evolve@gagnier.com